Tempest Therapeutics Stock (NASDAQ: TPST)

Tempest Therapeutics

TEMPEST THERAPEUTICS INC

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Alphabet.Google.Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMBO

DBGI

ENSC

GLYC

GOOG

GOOGL

LGMK

NRDS

PLRZ

QRVO

RDDT

RHHBY

SHPH

SNAP

SPRO

STBX

THRY

Tempest Therapeutics, Inc. - Common Stock

TPST

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

cancer

Biotech

Equities

Health Care

Contracts

General

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients with unresectable hepatocellular carcinoma.

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Small Cap

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Therapeutics Inc

Press Releases

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Earnings

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest to Participate in the Piper Sandler 36th Annual  Healthcare Conference

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Tempest Reports Year End 2024 Financial Results and  Provides Business Update

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kala Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

OSR Holdings

OS Therapies

Pluri

Rallybio

RenovoRx

Tenax Therapeutics

Scotiabank

HC Wainwright & Co.

Piper Sandler

Jefferies

Ladenburg Thalmann

Comments

Tempest Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga